ArticlePediatric research2026
Temporal trends in respiratory syncytial virus-related infant mortality and hospitalizations in the United States.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundRespiratory syncytial virus (RSV) is a leading cause of infant mortality and morbidity, yet national trends in RSV outcomes, particularly during the COVID-19 era, are not well defined. This study evaluated temporal patterns in RSV-related infant mortality and hospitalizations across the United States.
methodsWe analyzed RSV-associated infant mortality data from 2007-2022 using the CDC WONDER database and hospitalization rates from 2018-2025 using the hospitalization surveillance network (RSV-NET). Infant mortality and hospitalization patterns were assessed by season, race/ethnicity, and birth weight.
resultsOver 16 years, RSV-related infant mortality remained relatively stable, with no statistically significant year-to-year variation. Mortality rates were disproportionately higher among Black or African American infants and those with low birth weight. Seasonal hospitalization patterns varied substantially: the 2020-2021 RSV season recorded the lowest hospitalization rate, likely reflecting widespread COVID-19 mitigation measures, whereas the 2022-2023 season recorded the highest rate since 2018.
conclusionAlthough infant RSV mortality has remained stable, persistent disparities exist, and hospitalization rates show substantial seasonal fluctuations. These findings provide critical baseline data for assessing the impact of emerging RSV immunization strategies and highlight the need for targeted strategies to reduce persistent inequities in infant outcomes in the post-COVID-19 era. IMPACT: RSV-related infant mortality in the United States has shown both stability and a sharp post-pandemic surge, with persisting disparities by sex, birthweight and race. This study integrates temporal, demographic, and geographic patterns to provide the national-level evidence of RSV mortality and hospitalization patterns among infants during COVID-19 era. These findings establish essential baseline estimates to evaluate effectiveness of preventive measures, while underscoring the urgency of targeted strategies to reduce disproportionate risks among vulnerable infants.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.